REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
— Patients treated with RGX-202 demonstrate consistent, robustmicrodystrophin expression and functional improvement compared to natural history in Phase I/II portion of AFFINITY DUCHENNE® trial supporting potential approval via the accelerated approval pathway — REGENXBIO continues to enroll patients in the confirmatory trial — First batches intended for commercial supply manufactured at in-house Manufacturing Innovation Center […]